Geron "bad reputation" for disappointment may continue to play out. Mayo's PR & CR work will eventually dominate the stock price.
This is the future of medicine--understanding and applying telomeres to cancer cells, stem cells and ageing cells.
These result's from Mayo and the PR's & CR's with take the stock to $10 (Piper Jaffary) soon, and will lead to a major alliance or buyout at a higher price (Roche, Gilead, Novartis, JNJ ???) --companies that have deep pockets and are looking for pipelines to the future.
Of course not.
Piper Jaffray (Duncan) has a put a $10 dollar target on Geron based upon Mayo's preliminary results, which are medical successes, where nothing has been available before. This is just chapter 1. The excitement is building, and the next chapter will be revealed in December at ASH. Telomeres are a gift from the "almighty" and involve cancer cures, stem cell reproduction, and the ageing process. Telomeres will be the foundation of many medical advances & new fortunes in the 21st century. Buy now, and enjoy the future.
I see $7 by the end of next week based upon pipeline potential, Nobel prize, Mayo successes, big pharms interest, plus Scarlett's mission to improve shareholder value and sell the company. Imetelstat looks like a medical advance that has "legs". As far as the major investment houses and banks, Geron is not on their radar yet. Telomeres have a dynamic future.
The abstract title itself gave away the good news from the study: "Imetelstat, a Telomerase Inhibitor, Induces Morphologic and Molecular Remissions In Myelofibrosis and Reversal of Bone Marrow Fibrosis."
Two words from that title stand out -- remissions and reversal. The Mayo Clinic study found that five patients out of 18 patients included in the abstract analysis achieved either complete remission or partial remission. Another three patients experienced clinical improvement. The four patients that achieved complete remission also experienced reversal of bone marrow fibrosis.
This drug seems to have put some very sick people into remission, and perhaps caused a cure (too early to tell). It will now be used now on people still in reasonably good health. This will be the start of 100 years of research, and many breakthroughs. Geron is in the driver's seat with telomeres (imetelstat), and will have a bright future as a company and with partners.
Portfolio diversification. Most balanced portfolio's limit the amount in anyone one stock. (10% of portfolio is common). Stocks that "take-off" have to be trimmed back occasionally.
Nobel Prize showed the potential of the science (telomeres), and clinic trails now strongly reinforce the science. This is like a "text book" written by "the almighty". There is 100 years of research and breakthroughs involved here.
Geron has as much potential as Amgen in its early days. It will fluctuate, with an upward bias, perhaps for years to come.
Jakafi is approved to treat myelofibrosis but only provides symptomatic relief -- mainly by reducing the size of a patient's enlarged spleen, a hallmark of the disease.
Imetelstat, on the other hand, appears to be effective in the bone marrow, meaning the drug could to slow or even stop the malignancies which cause diseases like myelofibrosis.
Here's a simple way to think about imetelstat's potential: Neither Jakafi nor any other similar (JAK inhibitor) drugs being studied in myelofibrosis today are capable of producing a complete remission (CR) or partial remission (PR). At best, these drugs only provide clinical improvement (CI) in myelofibrosis patients.
We will find out soon. I think there is some precautionary profit taking as a hedge to possible "not-so-good" news. The general information still seems positive.
(AP, 11/5/13) Sterne Agee analyst Andrew Huang said the deal "increases the likelihood that Apple will replace Gorilla Glass with sapphire, which would be a marginal negative for Corning." He noted that Corning supplies Gorilla Glass for many other phone, tablet and notebook computer makers besides Apple.
Corning spokesman Daniel Collins declined to comment on the Apple-GT deal, but he said that "we do not believe that sapphire will gain a significant volume of the cover glass market."
"Sapphire weighs more than Gorilla Glass, about 1.6 times more and there are significant questions if it can be produced at the thinness necessary to compete with glass," Collins added in an email. "Our testing has shown that once sapphire is damaged, it is much more susceptible to breakage than Gorilla Glass."
The observed 100% hematologic response rate in the updated data set, accompanied by a molecular response rate of 88% among the patients who had a JAK2 V617F mutation, are consistent with the data reported at ASH last year," said Prof. Baerlocher. "Imetelstat continues to be well tolerated in this trial. With no patients on treatment losing hematologic response, and molecular responses maintained in 86% of the patients, the drug also appears to have good durability of its effects on the disease."
GERN Duncan, PhD, Charles 2013-11-01 Overweight $6 12 months -----Geron is being recommended By Piper Jaffray. It seems that Duncan has the right background, and inputs from Mayo, to know what he is talking about. It looks like a "solid hit" that will at least be a single.
Still trying to verify. It is FAKE until verified. Stop playing games, and post something that can be confirmed. There are "tricksters" on this board.